* Q4 sales 4% above our ests. at SEK 231m, for 6% org.
Redeye retains its positive view of CombinedX following the Q4 report.
* We keep our estimates unchanged... * ...and expect ~10-11% adj.
NoHo Partners reported Q4 EBIT of EUR 11.8m (-3.7% y/y), 4% above Vara Research consensus and 6% abo...
Redeye comments on Hansa Biopharma's Q4 report. Revenues were SEK76m in the quarter, a strong beat o...
Taaleri’s Q4 2025 continuing earnings of EUR 12.2m increased by 17% y/y and came 18% above our estim...
Siili's Q4 sales missed our estimate by 7% as domestic operations saw a clear decline and overall th...
Nelly delivered a decent Q4 report in our view with c.
Redeye provides a research update after Optomed’s Q4 2025 report.
Redeye updates its view following CTEK’s Q4 report.
Inderes’s Q4 report was well in line with our forecast and we highlight the improved activity in the...
Q4 showed a long-awaited return to organic growth driven by sales in Europe, while sales in the Amer...
Xer Tech är ett UAV-bolag som utvecklar och säljer hybridelektriska drönarsystem för tunga lyft och ...
Nettoomsättningen steg till 7 750 mkr med 4% organisk tillväxt och sex nya förvärv, inklusive intåg ...
Actic has delivered an impressive turnaround, driven by good execution and greater efficiency.
Redeye leaves a short comment following Cinclus’ announcement of having received positive CMC feedba...
Solteq reports Q4 figures on February 12. Despite a December guidance cut and change negotiations an...
Aspo reports Q4 results on Feb 16. ESL should see more significant earnings gains from now on as out...
Redeye provides an initial comment on the Q4 2025 report from Sdiptech, where adjusted EBITA in core...
* Sales -5% vs ABG, adj. EBITA +23% on lower opex * West and Central continue to struggle, UK positi...